Johnson & Johnson
Johnson & Johnson
Your view on JNJ
Overview
What the company does, where it operates, and who runs it.
About Johnson & Johnson
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Joaquin Duato
- Headquarters
- One Johnson & Johnson Plaza, New Brunswick, NJ, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Joaquin Duato
- Headquarters
- One Johnson & Johnson Plaza, New Brunswick, NJ, US
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue.
The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand.
Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Johnson & Johnson, and the rating behind it. JNJ last traded at $263.81, 40.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Johnson & Johnson. Starting points for Johnson & Johnson: P/E 40.0, EPS $6.58, beta 0.23 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Johnson & Johnson. Johnson & Johnson paid $5.28 per share over the last year — a 2.0% yield at the current $263.81 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Johnson & Johnson. Trailing twelve-month EPS for Johnson & Johnson stands at $6.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Johnson & Johnson. Johnson & Johnson has reported as a listed company since 1943. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Johnson & Johnson valued side by side against its closest peers. Johnson & Johnson is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Johnson & Johnson, and how their positions are changing. At a $635.76B market value, institutional positions materially move Johnson & Johnson's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Johnson & Johnson executives and directors. Shares of Johnson & Johnson have traded between $140.68 and $200.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Johnson & Johnson. Johnson & Johnson is a $635.76B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Johnson & Johnson. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Johnson & Johnson. Coverage tracks Johnson & Johnson within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
Comments on Johnson & Johnson (1)
I chose this stock for the Stock Picker University Challenge to fill my healthcare services slot because Johnson and Johnson is a relative low risk stock with a beta of only 0.23 and has beaten many of its earnings estimates.